Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double posi… Read more
Phio Pharmaceuticals Corp (PHIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.212x
Based on the latest financial reports, Phio Pharmaceuticals Corp (PHIO) has a cash flow conversion efficiency ratio of -0.212x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.08 Million) by net assets ($9.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Phio Pharmaceuticals Corp - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Phio Pharmaceuticals Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Phio Pharmaceuticals Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Phio Pharmaceuticals Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SSB Bancorp Inc
PINK:SSBP
|
-0.518x |
|
BWYS Group Berhad
KLSE:0313
|
-0.001x |
|
Eagle Filters Group Oyj
HE:EAGLE
|
-2.559x |
|
ECA
KLSE:0267
|
0.036x |
|
ASM INT (AVS.SG)
STU:AVS
|
0.086x |
|
Netlinkz Ltd
AU:NET
|
0.084x |
|
Mobio Technologies Inc
V:MBO
|
0.101x |
|
Goldenwell Biotech Inc
PINK:GWLL
|
-0.684x |
Annual Cash Flow Conversion Efficiency for Phio Pharmaceuticals Corp (2011–2024)
The table below shows the annual cash flow conversion efficiency of Phio Pharmaceuticals Corp from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.72 Million | $-7.11 Million | -1.506x | -8.29% |
| 2023-12-31 | $7.73 Million | $-10.75 Million | -1.391x | -24.28% |
| 2022-12-31 | $10.84 Million | $-12.13 Million | -1.119x | -106.95% |
| 2021-12-31 | $21.93 Million | $-11.86 Million | -0.541x | +20.04% |
| 2020-12-31 | $13.02 Million | $-8.80 Million | -0.676x | +55.04% |
| 2019-12-31 | $5.75 Million | $-8.64 Million | -1.504x | -171.56% |
| 2018-12-31 | $13.58 Million | $-7.52 Million | -0.554x | +89.33% |
| 2017-12-31 | $1.83 Million | $-9.51 Million | -5.190x | -626.05% |
| 2016-12-31 | $10.86 Million | $-7.76 Million | -0.715x | +13.14% |
| 2015-12-31 | $8.89 Million | $-7.32 Million | -0.823x | +70.88% |
| 2014-12-31 | $2.75 Million | $-7.76 Million | -2.826x | -121.32% |
| 2013-12-31 | $4.94 Million | $-6.31 Million | -1.277x | -247.33% |
| 2012-12-31 | $-5.84 Million | $-5.06 Million | 0.867x | -94.91% |
| 2011-12-31 | $-587.00K | $-9.99 Million | 17.017x | -- |